Sign InBreakout Stocks of Week 28 @ GER
NASDAQ was up last week (week 27) by 2.04% ending at 25,813.43 points after gaining 515.81 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Rio Tinto Group GER:RIO1. This stock has had a buy signal since Jul 03, 2026 when the price was 82.53€ , but have so far fallen 0% to 82.53€. Some other companies are on our watchlist to, among these are which all got a breakout pattern emerging.
| Date | Company | Price | Week 28 |
|---|---|---|---|
| Rio Tinto Group | 82.53€ | 79.38€ | -3.82% |
| Aurubis Ag | 180.50€ | 170.40€ | -5.60% |
The Rio Tinto Group stock price gained 0.0728% on the last trading day (Friday, 3rd Jul 2026), rising from 82.47€ to 82.53€. During the last trading day the stock fluctuated 1.25% from a day low at 82.48€ to a day high of 83.51€. The price has been going up and down for this period, and there has been a -3.67% loss for the last 2 weeks. Volume fell on the last day by -10 thousand shares and in total, 26 thousand shares were bought and sold for approximately 2.18€ million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Rio Tinto Group holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Rio Tinto Group:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
The Aurubis AG stock price gained 3.97% on the last trading day (Friday, 3rd Jul 2026), rising from 173.60€ to 180.50€. During the last trading day the stock fluctuated 3.26% from a day low at 174.80€ to a day high of 180.50€. The price has been going up and down for this period, and there has been a -7.44% loss for the last 2 weeks. Volume fell on the last day by -100 thousand shares and in total, 94 thousand shares were bought and sold for approximately 16.98€ million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Aurubis AG holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Aurubis AG:
Aurubis AG processes metal concentrates and recycling materials in Germany. The company processes scrap metals, organic and inorganic metalbearing recycling raw materials, and industrial residues. It also offers wire rods and specialty wires, shapes, bars and profiles, industrial rolled products, and architectural rolled products. In addition, the company also produces gold, silver, lead, lead-bismuth alloy, lead-antimony litharge, tellurium metals, and tellurium dioxide. Further, the company engages in the recycling of copper, copper scrap, alloy scrap and other recycling materials, precious metals, and other non-ferrous metals; and product businesses. Additionally, it produces sulfuric acid, iron-silicate, smelter intermediates, and selenium, as well as produces various products from purchased copper and copper alloy scrap, electronic scrap, and industrial residues. The company was formerly known as Norddeutsche Affinerie AG and changed its name to Aurubis AG in April 2009. Aurubis AG was founded in 1866 and is headquartered in Hamburg, Germany.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
SRPT
$17.02
|
5.52% | Jun 29 |
ROP
$331.60
|
4.54% | Jun 24 |
JLL
$299.78
|
4.87% | Jun 24 |
NESR
$25.07
|
16.83% | Jun 23 |
CAG
$13.43
|
5.36% | Jun 23 |
